PRESS Act

HR7184, titled the "Preventing Rogue Equipment for Synthetic Substances Act" or "PRESS Act," was introduced in the House of Representatives on January 21, 2026. It has been referred to the Committee on Energy and Commerce and the Committee on the Judiciary for consideration. The bill's primary objective is to amend the Controlled Substances Act to establish extraterritorial jurisdiction over the manufacture and distribution of equipment, such as tableting machines, encapsulating machines, press punches, die systems, and gelatin capsules, when there is intent or knowledge that such equipment will be used to produce controlled substances or listed chemicals for unlawful importation into the United States. This bill does not authorize or appropriate any specific funding. Its impact is purely regulatory, focusing on criminalizing and preventing the illicit trade of manufacturing equipment used in the production of counterfeit drugs. Therefore, there is no direct money trail associated with this legislation in its current form. The bill seeks to expand the scope of existing law to target the supply chain of illicit drug manufacturing equipment. Structural winners, if this bill were to pass, would primarily be legitimate manufacturers and distributors of pharmaceutical equipment who operate within legal frameworks, as the bill aims to curb illicit competition. However, no specific publicly traded companies are directly named or implicated as primary beneficiaries or losers in the bill text. The focus is on preventing illegal activities rather than promoting specific industries. The bill's provisions could indirectly affect companies involved in the legitimate manufacturing and distribution of such equipment by potentially increasing scrutiny or compliance requirements, though the bill text does not specify new regulatory burdens for legal operators. As of April 28, 2026, the bill is in the early stages of the legislative process, having only been introduced and referred to committees. The next steps would involve committee hearings, potential markups, and votes within the assigned committees before it could be considered by the full House. Given its early stage, the timeline for potential passage is uncertain, and significant legislative hurdles remain. The bill has 29 cosponsors, indicating some level of bipartisan support, but this does not guarantee passage.